Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato(2-)]cobaltate(1-)

Endpoint summary

Description of key information

Acute oral toxicity:

Data available for the structurally and functionally similar read across chemicals has been reviewed to determine the acute oral toxicity of the test chemical Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato(2-)]cobaltate(1-) (CAS no.: 85959-75-7). The studies are as mentioned below:

1. Acute oral toxicity study was conducted in rats using test chemical at the dose concentration of 15000mg/kg bw. No Mortality was observed at dose 15000 mg/kg bw. Hence, LD50 value was considered to be >15000 mg/kg bw, when rats were treated with test chemical orally.

2. Acute oral toxicity study was conducted by using given test chemical in rats at the concentration of 16000 mg/kg bw. No Mortality was observed at dose16000 mg/kg bw. Hence, LD50 value was considered to be >16000 mg/kg bw, when rats were treated with test chemical via oral route.

Thus, based on the above summarised studies, Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato (2-)]cobaltate(1-) (CAS no.: 85959-75-7) and it’s structurally similar read across substances, it can be concluded that LD50 value is >2000 mg/kg bw. Thus, comparing this value with the criteria of CLP regulation, Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato(2-)]cobaltate(1-) (CAS no.: 85959-75-7) cannot be classified for acute oral toxicity. Hence, Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato(2-)]cobaltate(1-) is not toxic in the dose range >15000 - >16000 mg/Kg bw, for acute oral toxicity.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

weight of evidence

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

data from handbook or collection of data

Remarks:

experimental data of read across substances

Justification for type of information:

Data for the target chemical is summarized based on the structurally similar read across chemicals

Reason / purpose for cross-reference:

read-across source

Reason / purpose for cross-reference:

read-across source

Qualifier:

according to guideline

Guideline:

other: As mentioned below

Principles of method if other than guideline:

WoE report is based on 2 acute oral toxicity studies as- WoE-2 and WoE-3.
Acute Oral toxicity test was carried out to study the effects of the test chemicals on rodents.

GLP compliance:

not specified

Test type:

other: not specified

Limit test:

no

Specific details on test material used for the study:

Name: Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato(2-)] cobaltate(1-)
Molecular Formula: C34H28Cl2CoN10O8-S2.H
Molecular Weight: 899.6361 g/mole
InChI:1S/C17H16ClN5O4S.C17H15ClN5O4S.Co/c2*1-10-16(17(25)23(22-10)12-5-3-4-11(18)8-12)21-20-14-9-13(6-7-15(14)24)28(26,27)19-2;/h3-9,19,24-25H,1-2H3;3-9,16H,1-2H3,(H,21,24);/q;-1;+3/p-2/b21-20+;;

Species:

rat

Strain:

other: 1. not specified 2. not specified

Sex:

not specified

Details on test animals or test system and environmental conditions:

1. not specified
2. not specified

Route of administration:

other: 1. oral: unspecified 2. oral: unspecified

Vehicle:

other: 1. not specified 2. unchanged (no vehicle)

Details on oral exposure:

1. not specified
2. not specified

Doses:

1. 15000 mg/kg bw
2. 16000 mg/kg bw

No. of animals per sex per dose:

1. not specified
2. not specified

Control animals:

not specified

Details on study design:

1. not specified
2. not specified

Statistics:

1. not specified
2. not specified

Preliminary study:

1. not specified
2. not specified

Sex:

not specified

Dose descriptor:

LD50

Effect level:

> 15 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: No mortality was observed

Sex:

not specified

Dose descriptor:

LD50

Effect level:

> 16 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: No mortality was observed

Mortality:

1. No mortality was observed at dose 15000 mg/kg bw.
2. No mortality was observed at dose 16000 mg/kg bw.

Clinical signs:

other: 1. not specified 2. not specified

Gross pathology:

1. not specified
2. not specified

Other findings:

1. not specified
2. not specified

Interpretation of results:

other: Not classified

Conclusions:

The test chemcial Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato(2-)]cobaltate(1-) (CAS no.: 85959-75-7) is not likely to be toxic in the dose range of >15000 - >16000 mg/Kg bw, for acute oral toxicity.

Executive summary:

Data available for the structurally and functionally similar read across chemicals has been reviewed to determine the acute oral toxicity of the test chemical Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato(2-)]cobaltate(1-) (CAS no.: 85959-75-7). The studies are as mentioned below:

1. Acute oral toxicity study was conducted in rats using test chemical at the dose concentration of 15000mg/kg bw. No Mortality was observed at dose 15000 mg/kg bw. Hence, LD50 value was considered to be >15000 mg/kg bw, when rats were treated with test chemical orally.

2. Acute oral toxicity study was conducted by using given test chemical in rats at the concentration of 16000 mg/kg bw. No Mortality was observed at dose16000 mg/kg bw. Hence, LD50 value was considered to be >16000 mg/kg bw, when rats were treated with test chemical via oral route.

Thus, based on the above summarised studies, Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato (2-)]cobaltate(1-) (CAS no.: 85959-75-7) and it’s structurally similar read across substances, it can be concluded that LD50 value is >2000 mg/kg bw. Thus, comparing this value with the criteria of CLP regulation, Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato(2-)]cobaltate(1-) (CAS no.: 85959-75-7) cannot be classified for acute oral toxicity. Hence, Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato(2-)]cobaltate(1-) is not toxic in the dose range >15000 - >16000 mg/Kg bw, for acute oral toxicity.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

16 000 mg/kg bw

Quality of whole database:

Data is Klimisch 2 and from report.

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information

Acute oral toxicity:

Data available for the structurally and functionally similar read across chemicals has been reviewed to determine the acute oral toxicity of the test chemical Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato(2-)]cobaltate(1-) (CAS no.: 85959-75-7). The studies are as mentioned below:

1. Acute oral toxicity study was conducted in rats using test chemical at the dose concentration of 15000mg/kg bw. No Mortality was observed at dose 15000 mg/kg bw. Hence, LD50 value was considered to be >15000 mg/kg bw, when rats were treated with test chemical orally.

2. Acute oral toxicity study was conducted by using given test chemical in rats at the concentration of 16000 mg/kg bw. No Mortality was observed at dose16000 mg/kg bw. Hence, LD50 value was considered to be >16000 mg/kg bw, when rats were treated with test chemical via oral route.

Thus, based on the above summarised studies, Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato (2-)]cobaltate(1-) (CAS no.: 85959-75-7) and it’s structurally similar read across substances, it can be concluded that LD50 value is >2000 mg/kg bw. Thus, comparing this value with the criteria of CLP regulation, Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato(2-)]cobaltate(1-) (CAS no.: 85959-75-7) cannot be classified for acute oral toxicity. Hence, Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato(2-)]cobaltate(1-) is not toxic in the dose range >15000 - >16000 mg/Kg bw, for acute oral toxicity.

Justification for classification or non-classification

Based on the above experimental studies on Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato (2-)]cobaltate(1-) (CAS no.: 85959-75-7) and it’s structurally similar read across substances, it can be concluded that LD50 value is >2000 mg/kg bw, for acute oral toxicity. Thus, comparing this value with the criteria of CLP regulation, Hydrogen bis[3-[[1-(3-chlorophenyl)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-4-yl]azo]-4-hydroxy-N-methylbenzenesulphonamidato (2-)]cobaltate(1-) cannot be classified for acute oral toxicity.